B-cell Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Phase I, Open Label, Dose-escalation Study Followed by a Safety Expansion Part to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL)
The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), to determine the maximum tolerated dose (MTD), the recommended dose and the lymphodepletion regimen. The purpose of the safety dose expansion is to assess the safety and tolerability of the RD for UCART19.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03671460 -
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
|
Phase 1 | |
| Recruiting |
NCT06056752 -
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT05016947 -
Venetoclax Plus Inotuzumab for B-ALL
|
Phase 1 | |
| Suspended |
NCT01974479 -
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Completed |
NCT00289562 -
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06034275 -
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04191941 -
Treatment of Hematological Malignancy With Novel CAR-T Cells.
|
Early Phase 1 | |
| Recruiting |
NCT05333302 -
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04129099 -
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
|
Early Phase 1 | |
| Recruiting |
NCT05651191 -
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
|
Early Phase 1 | |
| Recruiting |
NCT04150497 -
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
|
Phase 1 | |
| Withdrawn |
NCT05571540 -
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03281551 -
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05379647 -
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
|
Phase 1 | |
| Withdrawn |
NCT04156659 -
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
|
Phase 2 | |
| Recruiting |
NCT04094311 -
Study of Out of Specification for Tisagenlecleucel
|
Phase 3 | |
| Completed |
NCT01207388 -
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
| Active, not recruiting |
NCT03467256 -
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
|
Phase 1/Phase 2 | |
| Terminated |
NCT04844086 -
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
|
Phase 1 | |
| Recruiting |
NCT05648019 -
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
|
Phase 2 |